Research Article
Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy
Table 4
Univariate and multivariate analyses of association between clinical parameters and time to metastasis.
| | Clinical features | Patient numbers | Univariate | Multivariate | HR†
(95% CI‡) | P-value | HR†
(95% CI‡) | P-value |
| | Stage (I vs II vs III) | 13 : 27 : 65 | - | 0.004∗ | 1.732
(1.029-2.915) | 0.040∗ |
| | Tumor site (Upper vs Middle vs Lower) | 28 : 48 : 29 | - | 0.430 | - | - |
| | Gender (Male vs Female) | 98 : 7 | 0.400 (0.068-0.850) | 0.027∗ | 2.146
(0.876-5.258) | 0.097 |
| | Age (≥ vs <60 years old) | 40 : 65 | 0.759 (0.417-1.327) | 0.316 | - | - |
| | Surgery (Yes vs No) | 38 : 67 | 1.814
(1.039-3.013) | 0.036∗ | 0.441
(0.232-0.839) | 0.013∗ |
| | Radiotherapy (4000~5000cGy vs >5000cGy) | 40 : 65 | 0.775
(0.455-1.334) | 0.363 | - | - |
| | Days from diagnosis to initial treatment (< v.s ≥29) | 57 : 48 | 1.161
(0.686-1.966) | 0.578 | - | - |
| | Days from diagnosis to complete treatment (< v.s ≥69) | 54 : 51 | 0.789
(0.460-1.334) | 0.369 | - | - |
| | Hematologic Markers |
| | Platelet count of pre-treatment (≥ vs <300,000/μL) | 34 : 71 | 0.510
(0.247-0.838) | 0.012∗ | 1.282
(0.642-2.560) | 0.484 |
| | Platelet count of post-treatment (≥ vs <300,000/μL) | 9 : 96 | 0.372
(0.060-0.681) | 0.010∗ | 2.926
(1.164-7.355) | 0.023∗ |
| | MPV§ (≥ vs <9.8fl) | 51 : 50& | 0.864
(0.504-1.476) | 0.588 | - | - |
| | Hemoglobin (≥ vs <14g/dL) | 17 : 88 | 1.502
(0.785-2.688) | 0.235 | - | - |
| | White blood count (≥ vs <10,000/μL) | 12 : 93 | 0.556
(0.171-1.281) | 0.139 | - | - |
| | Absolute Neutrophil count (≥ vs <4483/μL) | 53 : 52 | 0.698
(0.408-1.177) | 0.175 | - | - |
| | Neutrophil percentage (≥ vs <73.4%) | 53 : 52 | 0.808
(0.476-1.365) | 0.423 | - | - |
| | Absolute Monocyte count (≥ vs <449/μL) | 53 : 52 | 1.000
(0.591-1.692) | 0.999 | - | - |
| | Monocyte percentage (≥ vs <7%) | 53 : 52 | 0.973
(0.574-1.647) | 0.917 | - | - |
| | Absolute lymphocyte counts (≥ vs <1042/μL) | 53 : 52 | 1.628
(0.968-2.819) | 0.065 | - | - |
| | Lymphocyte percentage (≥ vs <16%) | 53 : 52 | 1.834
(1.100-3.225) | 0.021∗ | 0.437
(0.065-2.943) | 0.398 |
| | Biomarker of Inflammation |
| | Platelet to- ratio (≥ vs <236) | 53 : 52 | 0.455
(0.254-0.750) | 0.003∗ | 0.955
(0.420-2.174) | 0.913 |
| | Platelet-to-Lymphocyte(%) ratio (≥ vs <14605) | 53 : 52 | 0.439
(0.248-0.727) | 0.002∗ | 1.129
(0.443-2.879) | 0.801 |
| | Neutrophil-to-Lymphocyte ratio (≥ vs <4.35) | 53 : 52 | 0.569
(0.330-0.955) | 0.033∗ | 0.506
(0.082-3.130) | 0.466 |
|
|
, hazard ratio; ‡CI, confidence interval; §MPV, mean platelet volume; , absolute lymphocyte count; &no data of 4 patients. |
